Valbenazine clinical trials
Also written NBI-98854 and Ingrezza.
How each study uses valbenazine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the valbenazine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 28 · Other 5
Neurocrine Biosciences (27) · Yale University (2) · Tanabe Pharma Corporation (1) · University of Chicago (1) · Virginia Commonwealth University (1) · Stephen Ruedrich (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test valbenazine.
- Feb 2027Efficacy of Valbenazine for the Treatment of Trichotillomania in AdultsPhase 2 · Yale University
- Jun 2027Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical DystoniaPhase 2 · Virginia Commonwealth University
Studies
Open first, then newest update. How each study uses valbenazine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 33
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingPhase 4Neurocrine BiosciencesNCT07105111Written as Valbenazine
- Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in CanadaEnrolling by invitationPhase 3Neurocrine BiosciencesNCT06312189Written as Valbenazine
- Valbenazine in Obsessive Compulsive DisorderNot yet recruitingPhase 2University of ChicagoNCT07111988Written as Valbenazine
- Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical DystoniaRecruitingPhase 2Virginia Commonwealth UniversityNCT06771323Written as Valbenazine
- Efficacy of Valbenazine for the Treatment of Trichotillomania in AdultsRecruitingPhase 2Yale UniversityNCT05207085Written as Valbenazine Oral Capsule
- Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseTerminatedPhase 3Neurocrine BiosciencesNCT04400331Written as Valbenazine
- Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyCompletedPhase 3Neurocrine BiosciencesNCT05206513Written as Valbenazine
- Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaCompletedPhase 3Neurocrine BiosciencesNCT05110157Written as Valbenazine
- Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedPhase 4Neurocrine BiosciencesNCT05859698Written as Valbenazine
- Efficacy and Safety of MT-5199 in Subjects With Tardive DyskinesiaCompletedPhase 2/3Tanabe Pharma CorporationNCT03176771Written as MT-5199
- Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With ValbenazineWithdrawnPhase 1Yale UniversityNCT05053321Written as Valbenazine
- Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for SchizophreniaTerminatedPhase 3Neurocrine BiosciencesNCT05654870Written as Valbenazine
- Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental DisabilitiesWithdrawnPhase 4Stephen RuedrichNCT06107829Written as Valbenazine Oral Capsule
- Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington DiseaseCompletedPhase 3Neurocrine BiosciencesNCT04102579Written as Valbenazine
- Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette SyndromeTerminatedPhase 2Neurocrine BiosciencesNCT03530293Written as Valbenazine
- Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette SyndromeTerminatedPhase 2Neurocrine BiosciencesNCT03732534Written as NBI-98854
- Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette SyndromeCompletedPhase 2Neurocrine BiosciencesNCT03444038Written as Valbenazine
- Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette SyndromeCompletedPhase 2Neurocrine BiosciencesNCT03325010Written as Valbenazine
- Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette SyndromeCompletedPhase 2Neurocrine BiosciencesNCT02879578Written as Valbenazine
- Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive DyskinesiaCompletedPhase 4Neurocrine BiosciencesNCT03891862Written as Valbenazine
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
Codes
What other systems call valbenazine · ClinicalTrials.gg INT000371
- MeSH (NLM) C000603978valbenazineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 54K37P50KHVALBENAZINEConfirmed FDA, NLM, Wikidata
- RxNorm 1918219Confirmed FDA, Wikidata
- Wikidata Q27089118valbenazineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152815ValbenazineOne source FDA
- DrugBank DB11915One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000603978 | valbenazine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 54K37P50KH | VALBENAZINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1918219 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27089118 | valbenazine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152815 | Valbenazine | One source FDA |
| DrugBank | DB11915 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.